| 摘要 |
The anti-inflammatory effect of the Invention was tested. Laboratory mice were used as a model. By injection of an adjuvant, an inflammatory reaction is stimulated in mice, which show all the symptoms of a strong inflammatory process in the organism after only 5 days. By its strong effect, the adjuvant induces the activation of Th2 cells, hyperproduction of IL-4, which is a costimulating cytokine for B cells. In the presence of an antigen, IL-4 activates specific B cells which produce antibodies of the IgE class (27). However, after the analysis of 21 genes which are involved in the inflammatory processes of a mouse, it was shown that, among other things, the Invention strongly activates NFkB and its translocation from cytoplasm into the nucleus in spleen cells. Besides that, by activation of relb genes, the Invention shifts the balance of Thl/Th2 in the direction of Th1 so that it stimulates recruiting of Th0 into Th1 and their multiplication. The Invention regulates the activity of clonally selected B lymphocytes, so that selective promoters, such as, e.g. IFN? and IL-10, stimulate the coding of molecules of the heavy chain of Ig and the production of IgG in the Fight against allergens. The preparation of the Invention is thus used for prevention of allergic reactions and has an immunoregulatory function when the symptoms of allergic reactions are already present. The Invention demonstrated an immunoregulatory effect through the activation of prevalence of the Th1 path and it stimulated the activation of the B-lymphocyte compartment all the way to plasma cells and the synthesis of IgG. The produced IgG enable macrophages to opsonize and phagocitize the allergen and thus neutralize it without the appearance of symptoms. After the application of the Invention, sensibilization of patients is prevented and the produced antibodies of the IgG class protect the person from the allergen specific only for him/her. |
